Outline in brief the main aim of safety pharmacology, and the differences between safety predictions driven by in vitro mechanistic profiling vs in vivo toxicity pre-clinical testing

• Outline in brief the main aim of safety pharmacology, and the differences between safety predictions driven by in vitro mechanistic profiling vs in vivo toxicity pre-clinical testing (e.g. describe strengths and limitations of each approach).

• Present the data from the analysis, appropriately labelled with descriptive legends and some descriptive text.

• The modulation of some drug targets is highly predictive of clinical toxicity. Using the safety pharmacology concepts taught in the lectures, discuss why one compound will likely be safer than the other. Support your prediction using published literature on the two drugs.